The OPTiM phase 3 trial, that lead to the approval of T-VEC, compared local T-VEC treatment with systemic GM-CSF treatment and reported improved response rate and also showed signs of enhanced systemic immune responses by tumor regression in non-injected lesions (76). This evidence concerns the gene CSF2 and neoplasm.